Artículos recomendados de autores cubanos: inmunoterapia del cáncer, vacunas, enfermedad celíaca, COVID-19

El sitio web cubano de Inmunología propone a nuestros usuarios la lectura de un grupo de artículos científicos de autores cubanos sobre los temas inmunoterapia del cáncer, vacunas, enfermedad celíaca y COVID-19.

– Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy. Front Immunol. 2022 Dec 9;13:1021828.
– Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. Vaccines (Basel). 2022 Dec 7;10(12):2087.
– Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba. Cancer Treat Res Commun. 2022 Dec 13;34:100670.
– Human B-1 cells are important contributors to the naturally-occurring IgM pool against the tumor-associated ganglioside Neu5GcGM3. Front Immunol. 2022 Nov 30;13:1061651.
– Anticuerpos antitransglutaminasa tisular en pacientes con síntomas gastrointestinales. Revista Cubana de Medicina, 2022;61(4).
– Nonspecific Effects of Infant Vaccines Make Children More Resistant to SARS-CoV-2 Infection. Children (Basel). 2022 Nov 29;9(12):1858.
– Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children. Int J Infect Dis. 2023 Jan;126:164-173.
– Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies. Front Oncol. 2022 Nov 2;12:951267.
– Anti-inflammatory mechanisms and pharmacological actions of phycocyanobilin in a mouse model of experimental autoimmune encephalomyelitis: A therapeutic promise for multiple sclerosis. Front Immunol. 2022 Nov 3;13:1036200.
– Biomarkers of sequela in adult patients convalescing from COVID-19. Adv Biomark Sci Technol. 2022;4:36-53.
– Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study. Hepatol Res. 2022 Nov 18.